Stock CLXPFCYBIN INC.
Add to a list
To use this feature you must be a member
Log inSign up

Cybin Inc. Stock

Equities

CLXPF

CA23256X4075

Biotechnology & Medical Research

Market Closed - Nyse
Other stock markets
 04:00:00 2025-03-17 pm EDT 		5-day change 1st Jan Change
7.650 USD +1.06% Intraday chart for Cybin Inc. +4.37% -13.27%
Feb. 10 Cybin Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2024 CI
Jan. 15 Cybin, Segal Trials Collaborate to Advance Major Depressive Disorder Treatment MT

Valuation: Cybin Inc.

Capitalization 230M 161M 147M 142M 124M 13.95B 252M 1.62B 617M 5.89B 603M 591M 23.91B P/E ratio 2025 *
-2.46x
P/E ratio 2026 * -2.24x
Enterprise value 119M 83.09M 76.1M 73.19M 63.99M 7.2B 130M 838M 318M 3.04B 311M 305M 12.34B EV / Sales 2025 *
-
EV / Sales 2026 * -
Free-Float
93.6%
Yield 2025 *
-
Yield 2026 * -
More valuation ratios * Estimated data

Chart: Cybin Inc.

Dynamic Chart

Latest news: Cybin Inc.

Cybin Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2024 Feb. 10 CI
Cybin, Segal Trials Collaborate to Advance Major Depressive Disorder Treatment Jan. 15 MT
Cybin Launches Strategic Clinical Site Partnerships to Support Paradigm, A Multinational Pivotal Phase 3 Program Evaluating Cyb003 for the Adjunctive Treatment of Major Depressive Disorder Jan. 15 CI
Cybin Inc. - Special Call Dec. 11
Cybin Says Phase 2 Data Show Potential Depression Drug Offers Relief Through 1 Year Nov. 18 MT
Cybin Inc. - Special Call Nov. 18
Cybin Reports Positive Phase 2 Data for Cyb003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder Nov. 18 CI
Cybin Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2024 Nov. 13 CI
Cybin Initiates PARADIGM Multinational Pivotal Phase 3 Program Evaluating Cyb003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results Nov. 13 CI
Cybin Inc. - Special Call 24-10-08
Cybin Inc. Announces Executive Appointments 24-10-01 CI
Cybin Inc.(NYSEAM:CYBN) added to S&P Global BMI Index 24-09-22 CI
Cybin Inc. Provides Corporate Update on Upcoming Clinical Milestones 24-09-20 CI
More news

Last Transcript: Cybin Inc.

Logo Cybin Inc.
Cybin Inc. - Special Call
Dec. 11
More transcripts

Analysts' recommendations: Cybin Inc.

HC Wainwright Adjusts Cybin Price Target to $5 From $10, Maintains Buy Rating 23-11-17 MT
Oppenheimer Adjusts Cybin Price Target to $4 From $4.50, Maintains Outperform Rating 23-08-15 MT
Canaccord Genuity Adjusts Price Target on Cybin to $5 From $6, Maintains Buy Rating 23-08-11 MT
Stifel Nicolaus Adjusts Cybin's Price Target to $1.13 From $1.10, Maintains Speculative Buy Rating 23-07-03 MT
Canaccord Genuity Trims Price Target on Cybin to $6 From $7, Maintains Buy Rating 23-07-03 MT
More recommendations

Press Releases: Cybin Inc.

Cybin : Corporate Presentation February 2025 Feb. 11 PU
Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights Feb. 10 BU
Cybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder Jan. 15 BU
Cybin Highlights 2024 Accomplishments and Upcoming Milestones for 2025 Jan. 13 BU
Cybin to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 Jan. 09 BU
More press releases

News in other languages: Cybin Inc.

Cybin berichtet über ein positives Treffen mit der FDA zum Ende der Phase 2 für CYB003 bei schweren depressiven Störungen und über die Planung eines Programms der Phase 3 24-03-14
Cybin annonce une réunion positive avec la FDA à la fin de la phase 2 pour le CYB003 dans le trouble dépressif majeur et la conception du programme de phase 3 24-03-14
Cybin reçoit la désignation de thérapie innovante de la FDA pour sa molécule psychédélique CYB003 et annonce des données de durabilité positives à quatre mois pour le traitement du trouble dépressif majeur 24-03-13
Annonce d’un placement privé sursouscrit de 150 millions USD 24-03-13
Cybin erhält von der FDA den Status eines Therapiedurchbruchs für sein neuartiges psychedelisches Molekül CYB003 und gibt positive Daten zur viermonatigen Dauerhaftigkeit bei schwerer depressiver Störung bekannt 24-03-13
More news

Quotes and Performance

1 day+1.06%
1 week+4.37%
Current month-6.25%
1 month-19.73%
3 months-19.22%
6 months+0.71%
Current year-13.27%
More quotes

Course Extremes

1 week
7.14
Extreme 7.14
7.71
1 month
6.81
Extreme 6.81
9.57
Current year
6.81
Extreme 6.81
10.73
1 year
6.5
Extreme 6.5
17.86
3 years
6.5
Extreme 6.5
43.32
5 years
6.5
Extreme 6.5
128.44
10 years
6.5
Extreme 6.5
128.44
More quotes

Managers and Directors: Cybin Inc.

Manager TitleAgeSince
Eric So PSD
 President 50 2020-11-04
Paul Glavine COO
 Chief Operating Officer 36 2016-10-12
Douglas Drysdale CEO
 Chief Executive Officer 55 2020-07-31
Director TitleAgeSince
Eric So CHM
 Chairman 50 2020-11-04
Paul Glavine BRD
 Director/Board Member 36 2016-10-12
Eric Hoskins BRD
 Director/Board Member 64 2020-11-04
More insiders

Bio Therapeutic Drugs

Add to a list
Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Change 5d. change 1-year change 3-years change Capi.($)
CYBIN INC. Stock Cybin Inc.
+1.06%+4.37%-56.24%-75.90% 159M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+1.78%+2.75%+26.02%+105.50% 130B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+1.73%-8.92%-29.66%-0.99% 71.37B
ARGENX SE Stock argenx SE
+1.67%+5.46%+63.42%+106.41% 36.42B
BEIGENE, LTD. Stock BeiGene, Ltd.
+2.27%+9.24%+55.92%+40.22% 27.77B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
+0.19%+3.27%+24.79%-40.11% 25.3B
BIONTECH SE Stock BioNTech SE
+1.40%-4.26%+9.06%-38.87% 23.87B
SUMMIT THERAPEUTICS INC. Stock Summit Therapeutics Inc.
-3.17%+11.90%+335.71%+543.13% 15.34B
WUXI BIOLOGICS (CAYMAN) INC. Stock WuXi Biologics (Cayman) Inc.
+4.32%+14.73%+87.33%-48.37% 14.05B
INSMED INCORPORATED Stock Insmed Incorporated
+1.59%+6.43%+202.37%+236.38% 13.86B
Average +1.21%+4.25%+71.87%+82.74% 35.78B
Weighted average by Cap. +1.39%+1.72%+42.30%+77.06%
See all sector performances

Financials

2025 *2026 *
Net sales - -
Net income -111M -77.67M -71.13M -68.41M -59.81M -6.73B -122M -783M -298M -2.84B -291M -285M -11.54B -115M -80.2M -73.45M -70.64M -61.76M -6.95B -126M -809M -307M -2.94B -301M -295M -11.91B
Net Debt -111M -77.83M -71.28M -68.55M -59.93M -6.75B -122M -785M -298M -2.85B -292M -286M -11.56B -19.5M -13.65M -12.5M -12.02M -10.51M -1.18B -21.4M -138M -52.29M -500M -51.15M -50.13M -2.03B
More financial data * Estimated data

Company Profile

Logo Cybin Inc.
Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N,N-dimethyltryptamine (DMT) and dDMT programs creates a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II. It has an intellectual property portfolio in the psychedelic drug development sector with over 30 patents granted and 160 patents pending. The Company operates in Canada, the United States, the United Kingdom, the Netherlands and Ireland.
Employees
50
Sector
Biotechnology & Medical Research
Calendar
Jun. 24 - Q4 2025 Earnings Release (Projected)
More about the company

Quotes

Date Price Change Volume
25-03-17 7.650 $ +1.06% 131,520
25-03-14 7.570 $ +3.70% 184,328
25-03-13 7.300 $ -0.54% 217,672
25-03-12 7.340 $ +2.66% 222,880
25-03-11 7.150 $ -2.46% 133,640

Delayed Quote Nyse, March 17, 2025 at 04:00 pm EDT

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
10.93CAD
Average target price
113.02CAD
Spread / Average Target
+934.04%
Consensus
Profit revisions
Estimate revisions

Quarterly revenue - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. CLXPF Stock